RVMD · Program file
daraxonrasib
Revolution Medicines, Inc. (RVMD)
When did Revolution Medicines, Inc. say daraxonrasib results would come?
On , Revolution Medicines, Inc. wrote in its SEC Form 10-Q: “RASolve 301: comparing daraxonrasib against docetaxel in patients with locally advanced or metastatic RAS mutant NSCLC who have been treated with immunotherapy and platinum-containing chemotherapy. We currently expect to complete enrollment in RASolve 301 in 2026, to enable an expected clinical readout in 2027; and” (Source)
Days left in the window the company stated: 438 · company’s wording: “in 2027”
Last checked: .
Watch this program: confirm your email to start one daily alert digest.
Program file
- Name as filed
- daraxonrasib
- Other names in filings
- RMC-6236 · RASolve 301
- Indication in the filing
- locally advanced or metastatic RAS mutant NSCLC
- Trials named in the same filing
- None listed
- Latest timing wording
- “RASolve 301: comparing daraxonrasib against docetaxel in patients with locally advanced or metastatic RAS mutant NSCLC who have been treated with immunotherapy and platinum-containing chemotherapy. We currently expect to complete enrollment in RASolve 301 in 2026, to enable an expected clinical readout in 2027; and”
- Source
- 10-Q · filed · SEC accepted · accession 0001193125-26-335104 · SEC original
- Last checked
Program RVMD-daraxonrasib.